A randomised, double blind, placebo-controlled trial of a two-week course of dexamethasone for adult patients with a symptomatic Chronic Subdural Haematoma (Dex-CSDH trial)

Submission date Recruitment status [X] Prospectively registered 07/11/2014 No longer recruiting [X] Protocol [X] Statistical analysis plan Overall study status Registration date 07/08/2015 Completed [X] Results [] Individual participant data **Last Edited** Condition category 18/09/2024 Injury, Occupational Diseases, Poisoning

Plain English summary of protocol

Background and study aims

Chronic subdural haematoma (CSDH) is a collection of liquefied blood between the surface of the brain and its outmost lining. It is especially common in older individuals and can happen with only a minor injury to the head. It can cause drowsiness, confusion, limb weakness and problems with mobility. In the UK, 5,000 people aged over 65 years are diagnosed with a CSDH each year. In the NHS, patients with severe symptoms usually undergo an operation to evacuate the CSDH. Patients with milder symptoms are usually actively monitored. Although about 80-85% of the patients tend to recover well from this operation, approximately 15-20% of patients will have a recurrence of the CSDH and require a further operation. This significantly reduces the chances of good recovery. A considerable body of evidence suggests that steroids can reduce the rate of recurrence and, in some cases, avoid the need for surgery altogether. However, steroids have side effects and it is not known whether the benefits outweigh the risks in this context. Currently, there is no high-quality evidence showing whether steroids should be used routinely for patients with CSDH. The Dex-CSDH study will provide this much needed evidence. The Dex-CSDH study will focus on symptomatic patients with CSDH and will compare the use of steroids against placebo ('dummy' treatment).

Who can participate?

All patients admitted to a participating neurosurgical unit with a CSDH will be considered for the study based on pre-specified criteria.

What does the study involve?

Once consent is in place, you will be assigned randomly (like the flip of a coin) to take either dexamethasone or placebo. The latter is sometimes called the 'dummy capsule'. It looks the same as the active treatment (dexamethasone) but does not contain any of the active ingredients. The treatment (dexamethasone or placebo) will be administered daily for 14 days on a tapering course, which reduces the dose over the 14-day study period. Neither you nor your doctor will know which treatment you are receiving – this is necessary in order to draw valid

conclusions at the end of the study. Before you leave the hospital we will assess your level of recovery. We will also ask you to fill in a short questionnaire pack at 3 and 6 months after leaving the hospital, as we would like to find out about your recovery and state of health.

What are the possible benefits and risks of participating?

There is no guaranteed benefit from taking part in this study. However, information collected in the study may benefit patients with a subdural haematoma in the future. Apart from the potential side effects of dexamethasone, there are no additional risks or disadvantages involved with taking part in this study. Dexamethasone is a medication used regularly in the treatment of many medical conditions. It is also widely used in many patients with conditions affecting the nervous system, e.g. brain tumours. The side effects of dexamethasone are rare with a short course such as the one in this study. You will continue to receive the standard care for your condition.

Where is the study run from?

The study is run from the University of Cambridge and Cambridge University Hospitals NHS Foundation Trust. It is expected that the majority of UK neurosurgical centres will participate.

When is the study starting and how long is it expected to run for? September 2014 to August 2019 (updated 09/06/2020, previously: May 2020 (as of 04/10/2018))

Who is funding the study? NIHR Health Technology Assessment Programme - HTA (UK).

Who is the main contact?
Prof Peter Hutchinson – Chief Investigator neurosurgsec@medschl.cam.ac.uk
Mr Angelos Kolias – Co-Chief Investigator angeloskolias@gmail.com

Contact information

Type(s)

Scientific

Contact name

Prof Peter Hutchinson

ORCID ID

https://orcid.org/0000-0002-2796-1835

Contact details

University of Cambridge
Dept of Clinical Neurosciences
Division of Neurosurgery
Box 167
Cambridge Biomedical Campus
Cambridge
United Kingdom

CB2 0QQ

_

neurosurgsec@medschl.cam.ac.uk

Type(s)

Public

Contact name

Ms Carol Davis-Wilkie

Contact details

Cambridge Clinical Trials Unit
Coton House
Level 6
Cambridge University Hospitals NHS Foundation Trust
Hills Road
Cambridge
United Kingdom
CB2 0QQ
+44 (0)1223 254921

carol.daviswilkie@addenbrookes.nhs.uk

Type(s)

Scientific

Contact name

Dr Ellie Edlmann

Contact details

Department of Clinical Neurosciences
Division of Neurosurgery
Box 167
Cambridge University Hospitals NHS Foundation Trust
Hills Road
Cambridge
United Kingdom
CB2 0QQ

eedlmann@nhs.net

Additional identifiers

Clinical Trials Information System (CTIS)

2014-004948-35

Protocol serial number

HTA 13/15/02

Study information

Scientific Title

A randomised, double blind, placebo-controlled trial of a two-week course of dexamethasone for adult patients with a symptomatic Chronic Subdural Haematoma (Dex-CSDH trial)

Acronym

Dex CSDH

Study objectives

Dexamethasone can improve the functional outcome of patients with symptomatic chronic subdural haematomas by reducing the rate of surgical intervention and the recurrence rate.

More details can be found at http://www.nets.nihr.ac.uk/projects/hta/131502

Ethics approval required

Old ethics approval format

Ethics approval(s)

NRES Committee North West - Haydock, 14/04/2015, REC ref: 15/NW/0171

Study design

Randomised double-blind placebo-controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Chronic subdural haematoma CSDH

Interventions

Patients will be randomized to take either dexamethasone or a placebo. The treatment will be administered daily for up to 14 days on a tapering course, which reduces the dose over the study period. The study period lasts for 6 months. At 3 months and again at 6 months short questionnaires will be completed, either face to face, by post or via telephone, to assess level of recovery.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Dexamethasone

Primary outcome(s)

Modified Rankin Scale (mRS) at 6 months post-randomisation

Key secondary outcome(s))

Current secondary outcome measures as of 26/08/2020:

Measured using patient records unless noted otherwise:

- 1. Number of CSDH-related surgical interventions undertaken during the index admission
- 2. Number of CSDH-related surgical interventions undertaken during subsequent admissions in the follow-up period
- 3. Glasgow Coma Scale (GCS) at discharge from NSU and at 6 months
- 4. mRS score at discharge from NSU and at 3 months
- 5. Barthel Index at discharge from NSU, 3 months and 6 months
- 6. Mortality (30-day and 6 months)
- 7. EuroQOL (EQ-5D) at discharge from NSU, 3 months and 6 months
- 8. Length of stay in NSU
- 9. Discharge destination from NSU
- 10. Length of stay in secondary care
- 11. Health-economic analysis
- 12. Adverse Events

(added 21/09/2020)

13. Post-operative recurrence is a tertiary outcome measure and is defined as a symptomatic recurrence requiring re-operation of a previously evacuated ipsilateral chronic subdural hematoma

Previous secondary outcome measures:

- 1. Rate of cSDH-related surgical interventions undertaken during the index admission
- 2. Rate of cSDH-related surgical interventions undertaken during subsequent admissions
- 3. Glasgow Coma Scale (GCS) at discharge from NSU and 6 months
- 4. mRS score at discharge from NSU and 3 months
- 5. Barthel Index at discharge from NSU, 3 months and 6 months
- 6. Mortality (30-day and 6 months)

Completion date

29/08/2019

Eligibility

Key inclusion criteria

- 1. Informed consent
- 2. Adults aged 16 or older
- 3. Symptomatic cSDH confirmed on cranial imaging (predominantly hypodense or isodense crescentic collection along the cerebral convexity on CT)

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

Total final enrolment

748

Key exclusion criteria

- 1. Patients who have already undergone surgical intervention for a cSDH during the same index admission
- 2. Condition with conditions where steroids are clearly contra-indicated (i.e. active infections)
- 3. Already on steroids
- 4. Enrolment in same study within last 12 months
- 5. Time interval from the time of admission to NSU to initiation of trial medication exceeds 72 hours
- 6. cSDH in presence of CSF shunt

Date of first enrolment

11/08/2015

Date of final enrolment

24/11/2018

Locations

Countries of recruitment

United Kingdom

England

Scotland

Wales

Study participating centre Cambridge University Hospitals NHS Foundation Trust United Kingdom CB2 0QQ

Study participating centre Imperial College Healthcare NHS Trust, London United Kingdom W2 1NY

Study participating centre Royal Victoria Infirmary Newcastle upon Tyne United Kingdom NE7 7DN

Study participating centre Derriford Hospital

Derriford Road Crownhill Plymouth United Kingdom PL6 8DH

Study participating centre
University Hospitals Birmingham NHS Foundation Trust
United Kingdom
B15 2TH

Study participating centre
University Hospital Southampton NHS Foundation Trust
United Kingdom
SO16 6YD

Study participating centre Queen Elizabeth University Hospital

1345 Govan Road Glasgow United Kingdom G51 4TF

Study participating centre Leeds General Infirmary

The Leeds Teaching Hospitals NHS Trust Great George Street Leeds United Kingdom LS1 3EX

Study participating centre Royal Hallamshire Hospital Sheffield Teaching Hospitals NHS Foundation Trust

Glossop Road Sheffield United Kingdom S10 2JF

Study participating centre
Brighton and Sussex University Hospital
Brighton
United Kingdom
BN2 1ES

Study participating centre
James Cook University Hospital
South Tees
United Kingdom
TS4 3BW

Study participating centre Royal Stoke University Hospital Stoke on Trent United Kingdom ST4 6QG

Study participating centre
St Georges University Hospitals
London
United Kingdom
SW17 0QT

Study participating centre
Hull Royal Infirmary
Hull
United Kingdom
HU3 2JZ

Study participating centre

Western General Hospital

Edinburgh United Kingdom EH4 2XU

Study participating centre Royal London Hospital

London United Kingdom E1 1FR

Study participating centre Aberdeen Royal Infirmary

Aberdeen United Kingdom AB25 2ZN

Study participating centre Royal Preston Hospital

Preston United Kingdom PR2 9HT

Study participating centre Queen's Hospital

Romford United Kingdom RM7 0AG

Study participating centre John Radcliffe Hospital

Oxford United Kingdom OX3 9DU

Study participating centre

Ninewells Hospital

Dundee United Kingdom DD2 1SG

Study participating centre
University Hospitals of Wales
Cardiff
United Kingdom
CF14 4XW

Study participating centre
Salford Royal NHS Foundation Trust
Manchester
United Kingdom
M6 8HD

Sponsor information

Organisation

Cambridge University Hospitals NHS Foundation Trust and University of Cambridge

ROR

https://ror.org/04v54gj93

Funder(s)

Funder type

Government

Funder Name

NIHR Health Technology Assessment Programme - HTA (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	31/12/2020	17/12/2020	Yes	No
Results article		01/03/2024	18/09/2024	Yes	No
Protocol article	protocol	04/12/2018		Yes	No
HRA research summary			28/06/2023	No	No
Statistical Analysis Plan	statistical analysis plan	10/12/2019	12/12/2019	No	No
Study website	Study website	11/11/2025	11/11/2025	No	Yes